OCUGEN, INC. Available-for-sale Securities, Amortized Cost Basis
OCUGEN, INC. (OCGN) had Available-for-sale Securities, Amortized Cost Basis of $900.00 thousand as of 2017-12-31, per its 10-K filed 2018-03-15.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-03-15
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $900.00K.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $1.82M.
- 2017-06-30: Available-for-sale Securities, Amortized Cost Basis $7.98M.
- 2017-03-31: Available-for-sale Securities, Amortized Cost Basis $8.01M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2017-12-31 | $900.00K 10-K · filed 2018-03-15 |
| 2017-09-30 | $1.82M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $7.98M 10-Q · filed 2017-08-10 |
| 2017-03-31 | $8.01M 10-Q · filed 2017-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |